Ophthalmic Immunotherapies

Immunotherapy is the suppression, modulation or stimulation of the immune system and traditionally occurs via drug-based treatments or newer classes of biological therapies.

The focus of our research and development is to assess the utility of mesenchymal stem and stromal cells (MSC) derived from placental tissue, which is also classed as a novel type of biological therapy, and assess whether they can minimize the deleterious effects in autoimmune diseases and other acute and chronic conditions where inflammation is uncontrolled. An over-reactive immune response can cause excessive inflammation to specific organs and tissue structures which will eventually cause them to become dysfunctional and fail.  Specifically, our research is focused on whether placental MSC therapy can modulate the immune system in a relatively common autoimmune condition known as Sjögren’s Syndrome. This disease impairs the function of exocrine glands such as the lacrimal glands around the eye and salivary glands in the mouth and, creates severe dryness of the eyes and mouth in addition to other systemic problems in more severe cases. In conjunction with investigating safety and efficacy of MSC therapy in ophthalmic clinical trials we are also in the process of developing novel molecular (gene expression) diagnostic panels to ascertain whether these may be used to guide the application of placental MSC therapy.

Evaluation and Modeling of Placental-Mesenchymal Stem/Stromal Cell (P-MSC) In Vitro Biodynamics

A Single-Centre, Randomised, Double-Blind, Placebo-Controlled Phase I/IIa Study Evaluating Safety, Tolerability and Lacrimal Gland Function Following Two Doses of Placental Mesenchymal Stem/Stromal Cell (P-MSC) Therapy Administered Intravenously in Patients with Moderate to Severe Sjögren’s Syndrome

Assessment of Health Economic Outcomes Relating to the Clinical Management of Sjögren’s Syndrome: A Preliminary Comparison Between Standard versus P-MSC Treatment Pathways

Development and Validation of a Molecular (Gene Expression) Classifier for Application within a P-MSC Treatment System in the Clinical Management of Sjögren’s Syndrome